Recursion Pharmaceuticals and NuScale Power.

Viewed this way, a definition is a decision mechanism. It distinguishes some elements of the universe from the others. Hence ...

If language is what makes us human, what does it mean now that large language models have gained “metalinguistic” abilities?

The lack of gains in productivity from AI could stall adoption and burst the economic bubble. Is there a rational explanation ...

New research shows AI can analyze language with skills rivaling human experts, challenging long-held ideas about intelligence ...

In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...